STABライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:37):

Stats
本日の出来高	1 004.00
平均出来高	25 252.00
時価総額	49 991.00
EPS	$0 ( 2024-03-11 )
次の収益日	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-02-22	Chandrasekhar Satishchandran	Buy	0
2021-09-09	Saluck Randy S.	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Barbarick Steve K	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Verny Lea	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-28	Markvicka Taunia	Buy	100 000	Common Stock, par value $0.005 per share

INSIDER POWER
0.00
Last 70 transactions
Buy: 2 421 695 \| Sell: 3 004 967

Statera Biopharma, Inc. 相関

10 最も正の相関
NAKD	0.946
AHPI	0.943
BHTG	0.935
TUEM	0.935
LGMK	0.932
MTEX	0.93
GRIN	0.923
AMGN	0.918
SMIT	0.917
PIII	0.917

10 最も負の相関
ALGM	-0.974
ATRS	-0.966
FRSG	-0.965
QIPT	-0.965
XPDB	-0.963
CRUS	-0.963
ITAQ	-0.963
VPCB	-0.962
NPAB	-0.961
ACQR	-0.961

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Statera Biopharma, Inc. 財務諸表

Annual	2021
収益:	$1.49M
総利益:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2021
収益:	$1.49M
総利益:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.471

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.126

Financial Reports:

No articles found.

Statera Biopharma, Inc.

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.